PubMed
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence
Anisimov VN, Khavinson VK, Popovich IG, et al. Biogerontology. 2003
Compare
Epithalon vs Retatrutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Epithalon
37 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
160
Sleep
160
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
155
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
4
0.2–0.4 mg
5
0.4–0.6 mg
14
1–2 mg
4
2+ mg
133
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 35 repeat reporters
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Sources (19)
Published sources linked on the Epithalon and Retatrutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Epitalon peptide induces telomerase activity in human somatic cells
Khavinson VK, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003
- Wiki study page →Source
PubMed
Peptide bioregulation of aging: results of a 15-year study
Khavinson VK. Bull Exp Biol Med. 2002
- Wiki study page →Source
ClinicalTrials.gov
Epitalon / epithalon studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Peptide promotes overcoming of the division limit in human somatic cell
Khavinson VKh, Bondarev IE, Butyugov AA, et al. Bulletin of experimental biology and medicine. 2004
- Wiki study page →Source
PubMed
Reparative effect of epithalon on pineal gland ultrastructure in gamma-irradiated rats
Khavinson VK, Yakovleva ND, Popuchiev VV, et al. Bull Exp Biol Med. 2001
- Wiki study page →Source
PubMed
Effect of pineal peptides on neuroendocrine system after pinealectomy
Khavinson VKh, Kvetnoi IM, Popuchiev VV, et al. Arkh Patol. 2001
- Wiki study page →Source
PubMed
Modulating effects of epithalamin and epithalon on the functional morphology of the spleen in old pinealectomized rats
Khavinson VK, Konovalov SS, Yuzhakov VV, et al. Bull Exp Biol Med. 2001
- Wiki study page →Source
PubMed
Aging of the pineal gland
Khavinson VKh, Golubev AG. Adv Gerontol. 2002
- Wiki study page →Source
PubMed
Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
Khavinson V, Razumovsky M, Trofimova S, et al. Neuro Endocrinol Lett. 2002
- Wiki study page →Source
Review Article
Peptides and Ageing
Khavinson VKh. Neuro Endocrinol Lett. 2002
- Wiki study page →Source
PubMed
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism
Khavinson V, Diomede F, Mironova E, et al. Molecules. 2020
- Wiki study page →Source
Review Article
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. J Am Acad Orthop Surg Glob Res Rev. 2026
- Wiki study page →Source
PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025